U.S. License Holder:
Sicor Biotech (Teva)
Date of License:
GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
8,058,398 (Modified G-CSF Polypeptide)
Amgen Manufacturing, Ltd.; Amgen Inc.
Teva Biopharmaceuticals USA, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.